Mazdutide
Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity
Innovent · Phase 1/2 · Active, not recruiting · Enrollment 98
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| IBI362 | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
| Tirzepatide | n/r | n/r | n/r | n/r |
Not shown
- IBI362: endpoint not reported
- Placebo: endpoint not reported
- Tirzepatide: endpoint not reported